Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial

Yong Huo, Lei Qian, Beijian Chen et al.|The Lancet Regional Health - Western Pacific|2023

Cited by 28